Navigation Links
Inhibikase Therapeutics to present at 5th International Congress on Polyomaviruses and Human Diseases
Date:4/25/2013

ATLANTA, April 25, 2013 /PRNewswire/ -- Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it will update the scientific and medical community on the development program for IkT-001Pro.  IkT-001Pro, a host-directed tyrosine kinase inhibitor in an extended release formulation, is intended to clear JC polyomavirus (JCV) infection, the causative agent of Progressive Multifocal Leukoencephalopathy (PML).  The Company will demonstrate the effectiveness of IkT-001Pro against patient-derived JCV isolated from the urine of patients chronically infected with virus, the first time a direct measure of antiviral potency against patient-derived virus has been possible.  A preliminary insight into clinical efficacy of the proposed therapy will also be presented, linking mechanism of action to direct control of virus in patients.  

(Logo: http://photos.prnewswire.com/prnh/20110517/CL02791LOGO)

JCV infection progresses to PML only in patients with chronic or drug-induced immune suppression, to include patients diagnosed with clinical AIDS or who are receiving monoclonal antibody treatment for MS, lupus, rheumatoid arthritis, leukemia or lymphoma.   IkT-001Pro is projected to clear the patient of chronic JCV infection prior to its transformation and entry into the brain, thereby acting as a form of preventative therapy for AIDS patients and/or patients on immunosuppressive therapy.

"The ability to isolate and replicate patient-derived virus and demonstrate antiviral potency for IkT-001Pro validates the mechanism of action of this medication against the viral infection that actually afflicts patients.  Combined with a preliminary clinical readout, Inhibikase may have found a path to control the PML development in at least some patients.  While further clinical evaluati
'/>"/>

SOURCE Inhibikase Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Immunomic Therapeutics Announces Interim Data Analysis of Phase I Study to Treat Japanese Red Cedar Allergy
2. PTC Therapeutics Appoints Mark Rothera As Chief Commercial Officer
3. DSM and DecImmune Therapeutics Sign Agreement to Develop N2 Pathway Blocking Antibody
4. Serina Therapeutics Announces Agreement Retaining Woodside Capital Partners as Advisor and Investment Bank
5. Serina Therapeutics Announces Worldwide Exclusive License Agreement with The Scripps Research Institute for Click Chemistry
6. Mast Therapeutics Presents MST-188 Data at 7Th Annual Sickle Cell Disease Research and Educational Symposium
7. Society for Brain Mapping and Therapeutics (SBMT) announce the formation of American Board of Brain Mapping, its 2013 award recipients and its Brain Mapping Day at the US Congress
8. Sorbent Therapeutics Initiates Phase 2b Clinical Trial of CLP-1001 for Treatment of Signs and Symptoms of Fluid Overload in Patients with Heart Failure
9. NewGen Therapeutics Presents Data on NT-113, A Novel Pan-ErbB Inhibitor, at American Association of Cancer Research
10. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
11. Spencer Trask Congratulates InVivo Therapeutics on its Recent Approvals from the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , Oct. 17, 2014  Training market researchers ... critical success factor in today,s highly competitive global ... research organizations that effectively and efficiently produce high ... service area. Effective training programs ... earn recognition from internal clients by developing analysts ...
(Date:10/17/2014)...  Amgen (NASDAQ: AMGN ) today announced ... president of Gladstone Institutes and Gladstone,s Robert W. and ... are pleased to welcome Dr. Sandy Williams ... , chairman and chief executive officer of Amgen. "Dr. ... his direct experience in our industry will both be ...
(Date:10/17/2014)... 17, 2014 ... announced the addition of the  "China Interventional ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... China impacted by ... consumption concept, dietary habit, way of working ...
Breaking Medicine Technology:Effective Training Programs for Market Research Groups can Boost Overall Organizational Success 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 3China Interventional Cardiovascular Device Industry Report 2014-2017 2China Interventional Cardiovascular Device Industry Report 2014-2017 3
... Va., Oct. 8 Mirixa Corporation, the leader ... hiring of Cheryl Hoffer as Vice President, Pharmacy ... Pharmacy Account Management team, supporting independent and chain ... The Pharmacy Account Management team also helps expand ...
... LAKE FOREST, Ill., Oct. 8 Hospira, Inc. (NYSE: ... pharmaceuticals, today signed a Business Cooperation Agreement with South ... outlines the business terms of a future distribution agreement ... Canada for eight biogeneric products that are currently under ...
Cached Medicine Technology:Mirixa Corporation Announces Key Pharmacy Network Hire 2Hospira, Celltrion, Enter Business Cooperation Agreement to Develop and Market Biogeneric Drugs 2Hospira, Celltrion, Enter Business Cooperation Agreement to Develop and Market Biogeneric Drugs 3
(Date:10/20/2014)... 20, 2014 My Clients Plus ( ... application. The new module enables easy administration and ... life-cycle quality care. , This application allows users such ... practice, attach a to-do item to a specific client, ... set up reoccurring reminders for follow-ups. It's designed ...
(Date:10/20/2014)... CA (PRWEB) October 20, 2014 AttorneyOne.com, a ... the latest information from the FDA on Sit and ... October 10 not to purchase or use Sit and Slim ... and Slim II is promoted as weight loss product on ... removed from the market in 2010 for safety reasons, can ...
(Date:10/20/2014)... Rockynol Retirement Community broke ground ... The $11 million project will include the latest in ... with full-service restaurant style dining. , “We are excited ... Assisted Living apartments,” said Kara Hanzie, Rockynol Executive Director ... of care and this investment is proof of our ...
(Date:10/20/2014)... 2014 Based on a proprietary ... imaging assays capable of determining DNA sequence, location ... these three dimensions of high-resolution data, dGH assays ... widest range of disease-causing genetic rearrangements, including chromosomal ... genomic tools, including today’s advanced sequencing technologies. , ...
(Date:10/20/2014)... Final Cut Pro X Plugin developers from ... theme for FCPX filmmakers . , “Fun, cool, and ... Citrus theme” Says Christina Austin, CEO of Pixel Film Studios. ... , Citrus comes with all the tools needed for a ... transitions for added style, a title screen for an introduction, ...
Breaking Medicine News(10 mins):Health News:My Clients Plus Announces New Workflow Management Software 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2
... ... ... ... ...
... has identified four aspects of immune system disturbance which ... different inherited risk factors which predispose to the disease ... the way towards improved diagnostics and treatments for the ... population, and lead to insights into related conditions such ...
... PCI Data Compliance ... ... card processing company for small to medium sized businesses. Recently, North American Bancard has ... provide the small to medium sized businesses of the area to take advantage of face-to-face ...
... Allergens not linked to wheezing in kids, study finds , ... early in life doesn,t affect a child,s risk of developing ... that infants were exposed to high levels of endotoxin and ... were anxious to find out, through a birth cohort study, ...
... exposure during pregnancy might increase chances of condition , ... mothers were exposed to a common but controversial chemical ... A (BPA) is a chemical commonly found in polycarbonate ... beverage cans. Production of the chemical started about 40 ...
... ... ... ... ...
Cached Medicine News:Health News:Multiple Medalist Kristina Groves Matches Hain Celestial's $5,000 Donation to Right to Play 2Health News:Multiple Medalist Kristina Groves Matches Hain Celestial's $5,000 Donation to Right to Play 3Health News:Multiple Medalist Kristina Groves Matches Hain Celestial's $5,000 Donation to Right to Play 4Health News:Multiple Medalist Kristina Groves Matches Hain Celestial's $5,000 Donation to Right to Play 5Health News:Multiple Medalist Kristina Groves Matches Hain Celestial's $5,000 Donation to Right to Play 6Health News:Multiple Medalist Kristina Groves Matches Hain Celestial's $5,000 Donation to Right to Play 7Health News:Multiple Medalist Kristina Groves Matches Hain Celestial's $5,000 Donation to Right to Play 8Health News:Pinpointing immune system disturbances in celiac disease 2Health News:North American Bancard in the Tri-Cities Area of East Tennessee 2Health News:Household Dirt Won't Raise Asthma Risk in Infants 2Health News:BPA May Raise Risk of Asthma in Kids 2Health News:BPA May Raise Risk of Asthma in Kids 3Health News:CareTech Solutions Presents Specialized Healthcare Call Center at HIMSS10 2Health News:CareTech Solutions Presents Specialized Healthcare Call Center at HIMSS10 3Health News:CareTech Solutions Presents Specialized Healthcare Call Center at HIMSS10 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: